BioSpace News Archive

SOPHiA GENETICS SA, a cloud-native software company in the healthcare space, announced the company will be participating in the following investor conferences.

Pfizer Inc. and BioNTech SE announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 14 newly-hired employees stock options to purchase an aggregate of 125,700 shares, and restricted stock units covering an aggregate of 46,350 shares, of BioCryst common stock.

Cardinal Health reported first quarter fiscal year 2023 revenues of $49.6 billion, an increase of 13% from the first quarter of last year.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal second quarter ended September 30, 2022.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 2b RE-THINC ESRD study of fesomersen.

Virax Biolabs Group Limited announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 2,330,000 shares of ordinary shares (or ordinary shares equivalents in lieu thereof) at a gross purchase price of $1.65 per share.

Peak Bio, Inc. today announced that it has entered into a Common Stock Purchase Agreement (the “Agreement”) with White Lion Capital, LLC (“White Lion Capital”).

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 18 new employees.

Rain Therapeutics Inc. today announced preliminary data in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.